Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.64 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.64 |
| ▸ | TTR | P02766 | 1/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 5/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.55 |
| ▸ | ALOX15B | O15296 | 2/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 2/20 | 0.43 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545326 | 1.00 | ESR1 (0.64) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL8983958 | 0.85 | THRA (0.47) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL31545514 | 0.84 | ESR1 (0.72) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43647 | 0.79 | ESR2 (1.00) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL29467332 | 0.79 | ESR2 (1.00) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL677723 | 0.79 | ESR2 (1.00) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL43648 | 0.79 | ESR2 (1.00) | ESR1ESR2TTRALOX15ALOX12 | |
| Aus-131 SCHEMBL2002128 | 0.79 | ESR2 (1.00) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL38662450 | 0.79 | ESR1 (0.76) | ESR1ESR2TTRALOX15ALOX12 | |
| SCHEMBL12914761 | 0.79 | ESR1 (0.76) | ESR1ESR2TTRALOX15ALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2981530-B1 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2020-02-12 | — | — | EP | disclosed |
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE | 2016-03-10 | — | — | US | disclosed |
| EP-2981530-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | The Administrators of the Tulane Educational Fund (US) | 2016-02-10 | — | — | EP | disclosed |
| WO-2014165723-A2 | ENHANCED OSTEOGENIC ACTIVITY OF DAIDZEIN ANALOGS ON HUMAN MESENCHYMAL STEM CELLS | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068542-A1 | Enhanced Osteogenic Activity of Daidzein Analogs on Human Mesenchymal Stem Cells | HPGDS, CXCL12, ALPG | ESR1 2035/4885ESR2 945/4885TTR 4881/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.